The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / OptionEyes


Subject:  Re: Musings Date:  9/17/2006  3:22 PM
Author:  keahou Number:  362 of 377

A positive sign that now may be the time for LEAPs, is the fact that almost 3 months have past since todays posts. What did he say? Buy when nobody wants them?

3 candadates for your perusal:


A very high price on this stock. A few LEAPs at the 100 strike for 2008 at $19 look attractive. Down from $124 in May. Look at the news:


The mighty have succumbed: MU and IFX. The rest will follow. Liscensee fees and royalties could exceed market expectations. Consolidation complete after that accomplishment. News:


Elan's MS drug, Tysabri returned to market 7/19/06. This is an extremely rare event in the annuals of the FDA. TEVA and other competing drugs firms have had a sometimes not too subtle of a "Scare" agenda in an attempt to blunt the uptake of this champion of efficacy for the MS patient. In Tysabri's previous 11/04-2/05 market exposure, only the US market was in play. The EU has approved use and Germany in particular is apparently very enthusiastic.

Elan has Wyeth as their partner in their Alzheimers drug developement of AAB-001. Friday, Wyeth announced positions for overall supervisor of this drug and another position for the responsiblity for its production. Phase 3 is rumored to be near implementation. Lots of political heat on the FDA to "Get with it". Look at Fri's action, almost a "White Marubozu.

Optional candadates:


133 million shares. Q3 #'s came in with a $700 million increase in cash equivalents. Nearly $1 billion in Q3? Shed 20+ billion obligations during bankrupcy. Market may soon pick up on this.


Down from $140/share in 2000. A light at the end of the litigation tunnel? That would be the catalyst. Dicey as always.

Mine, what are yours?

Copyright 1996-2018 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us